You are here: Industry Insights > Eisai

News List

Eisai and Cogstate Expand Agreement for Global Development and Commercialization of Digital Cognitive Assessment Technologies prnasia
October 26, 2020
Eisai Co., Ltd. and Cogstate, Ltd. announced that the companies have entered into a collaboration whereby Eisai has secured the global development rights and exclusive commercialization rights of all cognitive function tests developed by Cogstate ...
Eisai Enters Joint Development Agreement for COVID-19 Therapeutics contractpharma
October 10, 2020
Aims to understand the mechanism of COVID-19 aggravation based on SARS-CoV-2 infection and to create drugs that prevent the aggravation of COVID-19.
Keytruda/Lenvima combo shows promise in hard-to-treat cancers pharmatimes
September 22, 2020
MSD (Merck) and Eisai have revealed new data from two trials under the LEAP clinical programme evaluating the combination of MSD’s PD-1 inhibitor Keytruda and Eisai’s oral tyrosine kinase inhibitor Lenvima.
Novel anti-amyloid drug BAN2401 enters Phase III trial in Alzheimer’s patients europeanpharmaceuticalreview
July 23, 2020
BAN2401 will be tested in various stages of Alzheimer’s disease progression to assess if it can slow the progression of cognitive decline.
Eisai Enters Joint Research Alliance to Create SLE Treatment contractpharma
July 14, 2020
Aims to create a Japan-originated therapeutic drug for systemic lupus erythematosus using Eisai’s new oral Toll-Like Receptor 7/8 inhibitor E6742.
US rejects MSD/Eisai's Keytruda Lenvima combo pharmatimes
July 10, 2020
MSD and Eisai have received a complete response letter (CRL) from the US Food and Drug Administration rejecting accelerated approval of a combination of Keytruda (pembrolizumab) and Lenvima (lenvatinib) for liver cancer.
US FDA declines to approve Merck and Eisai’s liver cancer combo therapy expresspharma
July 10, 2020
The FDA's complete response letter cited lack of sufficient evidence that the Keytruda-Lenvima combination therapy had a meaningful advantage over available treatments for the condition.
Numab closes $23.6m Series B round led by Asian investors pharmaceutical-technology
March 11, 2020
Swiss biotech Numab has raised CHF22m ($22.7m) in a Series B financing round, which attracted multiple new investors from Asia, including 3SBio, Mitsubishi UFJ Capital and Eisai, as well as a company board member Dr Daniel Vasella.
Eisai preps for launch with insomnia med Dayvigo after buying out Purdue fiercepharma
December 27, 2019
Once partners with the now-embattled Purdue on an insomnia treatment, Eisai bought a full stake in the drug earlier this year––taking on its full development and marketing costs, too.
Gilead and Eisai Enter Into Agreement in Japan for the Co-Promotion of the Investigational Rheumatoid Arthritis Therapy Filgotinib, Pending Regulatory Approval firstwordpharma
December 24, 2019
Approximately 600,000 to 1 million people are living with RA across Japan, and despite available options, many still do not experience disease remission.

Previous page 1 2 3 4 5 6 7 8 9 10 Next page